Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers
AbbVie and Teva Pharmaceuticals pushed back Thursday after buyers of the cholesterol drug Niaspan asked the Third Circuit to consider one of its 2022 opinions before deciding whether to deny them...To view the full article, register now.
Already a subscriber? Click here to view full article